- Home
- GXAI vs PULM Comparison
GXAI vs PULM Comparison
Compare GXAI & PULM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GXAI | PULM |
|---|---|---|
| Founded | 2021 | 2003 |
| Country | United States | United States |
| Employees | 3 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.4M | 5.2M |
| IPO Year | 2022 | 2013 |
Fundamental Metrics
Financial Performance| Metric | GXAI | PULM |
|---|---|---|
| Price | $0.40 | $1.37 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 119.5K | 29.7K |
| Earning Date | 11-20-2026 | 11-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 71.35 | 46.18 |
| EPS | ★ N/A | N/A |
| Revenue | $1,933,030.00 | ★ $7,910,000.00 |
| Revenue This Year | $462.16 | N/A |
| Revenue Next Year | $30.00 | $67.27 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 47901.74 | 5069.93 |
| 52 Week Low | $0.41 | $1.06 |
| 52 Week High | $5.26 | $4.98 |
Technical Indicators
Market Signals| Indicator | GXAI | PULM |
|---|---|---|
| Relative Strength Index (RSI) | 37.21 | 47.35 |
| Support Level | N/A | $1.23 |
| Resistance Level | $0.52 | $1.46 |
| Average True Range (ATR) | 0.04 | 0.15 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 27.02 | 62.59 |
Price Performance
Historical ComparisonAbout GXAI Gaxos.ai Inc.
Gaxos.AI Inc is a technology company focused on reshaping the way people interact with artificial intelligence across everyday life and high-impact industries. It is engaged in building a portfolio of AI-powered solutions designed to make advanced technology more practical, accessible, and transformative. The company's portfolio spans defense, health and wellness, entertainment, and productivity - bringing intelligent tools to markets where innovation can drive meaningful real-world outcomes. It operates as a single operating segment technology-based company that is developing applications aimed at redefining the way it utilizes artificial intelligence (AI) to optimize the user experience.
About PULM Pulmatrix Inc.
Pulmatrix Inc is a biopharmaceutical company focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented dry powder delivery technology, iSPERSE. Its pipeline of clinical assets includes PUR3100 for the treatment of acute migraine, PUR1800 for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD), and PUR1900 for the treatment of ABPA in patients with asthma and in patients with cystic fibrosis (CF).